SCHEMBL16340374

SCHEMBL16340374

C=CCN(CC=C)c1ccc(C(=O)c2ccccc2C(=O)OC)c(O)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.54
▸ KMT2A Q03164 1/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ KDM4E B2RXH2 2/20 0.50
▸ GAA P10253 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ LMNA P02545 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ ALOX5 P09917 1/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ PGR P06401 1/20 0.42
▸ ADORA3 P0DMS8 1/20 0.42
▸ AR P10275 1/20 0.42
▸ CHRM1 P11229 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ALOX15 P16050 1/20 0.42
▸ TBXA2R P21731 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6441612 0.87 CYP3A4 (0.56) MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E
SCHEMBL3854600 0.85 KMT2A (0.70) MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E
SCHEMBL1959291 0.85 SMN1; SMN2 (0.74) MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E
SCHEMBL7734598 0.83 SMN1; SMN2 (0.52) MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E
SCHEMBL4735417 0.81 GAA (0.76) MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E
SCHEMBL2901749 0.79 SMN1; SMN2 (0.65) MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E
Benzoic Acid SCHEMBL28747841 0.79 MEN1 (0.72) MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E
SCHEMBL16687946 0.79 KMT2A (0.57) MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E
SCHEMBL10869821 0.79 MEN1 (0.57) MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E
SCHEMBL2901653 0.79 SMN1; SMN2 (0.67) MEN1KMT2ASMN1; SMN2L3MBTL1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160152554-A1 METHOD FOR PRODUCING 2-(4-N,N-DIALKYLAMINO-2-HYDROXYBENZOYL) BENZOATES DSM IP ASSETS B.V. (NL) 2016-06-02 — — US claimed
EP-3013788-A1 METHOD FOR PRODUCING 2-(4-N,N-DIALKYLAMINO-2-HYDROXYBENZOYL) BENZOATES DSM IP Assets B.V. (NL) 2016-05-04 — — EP claimed
WO-2014207002-A1 METHOD FOR PRODUCING 2-(4-N,N-DIALKYLAMINO-2-HYDROXYBENZOYL) BENZOATES DSM IP ASSETS B.V. (NL) 2014-12-31 — — WO claimed
US-9682920-B2 Method for producing 2-(4-N,N-dialkylamino-2-hydroxybenzoyl) benzoates DSM IP ASSETS B.V. (NL) 2017-06-20 — — US disclosed
US-20160152554-A1 METHOD FOR PRODUCING 2-(4-N,N-DIALKYLAMINO-2-HYDROXYBENZOYL) BENZOATES DSM IP ASSETS B.V. (NL) 2016-06-02 — — US disclosed
EP-3013788-A1 METHOD FOR PRODUCING 2-(4-N,N-DIALKYLAMINO-2-HYDROXYBENZOYL) BENZOATES DSM IP Assets B.V. (NL) 2016-05-04 — — EP disclosed
WO-2014207002-A1 METHOD FOR PRODUCING 2-(4-N,N-DIALKYLAMINO-2-HYDROXYBENZOYL) BENZOATES DSM IP ASSETS B.V. (NL) 2014-12-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152554-A1 METHOD FOR PRODUCING 2-(4-N,N-DIALKYLAMINO-2-HYDROXYBENZOYL) BENZOATES HAAO, HAO2, HPD MEN1 3880/4885KMT2A 1038/4885SMN1; SMN2 3951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback